Christopher Gostout Net Worth

Christopher Gostout biography

Dr. Christopher J. Gostout M.D serves as Chief Medical Officer of the Company. Since January 2017, Dr. Gostout has served as the Chief Medical Officer of Apollo. Between August 2013 and December 31, 2016, Dr. Gostout served as a consultant to Apollo. From 1983 to 2016, Dr. Gostout served in the Mayo Clinic in the Division of Gastroenterology and Hepatology. From 2005 to December 2016, he maintained a joint appointment in the Department of Surgery. In July 2000, he became a Professor of Medicine in the Mayo Clinic College of Medicine and the Director of the Developmental Endoscopy and Research Unit in 1998. Dr. Gostout holds a B.S. in Biology from Villanova University and a M.D. from the State University of New York Downstate Medical Center.

What is the salary of Christopher Gostout?

As the Chief Medical Officer of Apollo Endosurgery Inc, the total compensation of Christopher Gostout at Apollo Endosurgery Inc is $1,156,870. There are no executives at Apollo Endosurgery Inc getting paid more.

How old is Christopher Gostout?

Christopher Gostout is 69, he's been the Chief Medical Officer of Apollo Endosurgery Inc since 2017. There are 2 older and 16 younger executives at Apollo Endosurgery Inc. The oldest executive at Apollo Endosurgery Inc is Dr. Christopher J. Gostout, 70, who is the Co-Founder & Chief Medical Officer.

What's Christopher Gostout's mailing address?

Christopher's mailing address filed with the SEC is 1120 S Capital of Texas Hwy #300, Austin, TX 78746, USA.

Insiders trading at Apollo Endosurgery Inc

Over the last 12 years, insiders at Apollo Endosurgery Inc have traded over $3,882,241 worth of Apollo Endosurgery Inc stock and bought 10,717,094 units worth $45,588,363 . The most active insiders traders include Holdings A/S Novo, Neil Gagnon oraz R Kent Jr Mc Gaughy. On average, Apollo Endosurgery Inc executives and independent directors trade stock every 41 days with the average trade being worth of $2,726,880. The most recent stock trade was executed by Jeffrey G. Black on 25 February 2022, trading 40,000 units of APEN stock currently worth $229,200.

What does Apollo Endosurgery Inc do?

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo Endosurgery Inc executives and stock owners

Apollo Endosurgery Inc executives and other stock owners filed with the SEC include:

• Christopher Gostout,
  Chief Medical Officer
• Todd Newton,
  Chief Executive Officer, Director
• John J. Molesphini,
  Exec. VP of Operations
• Bret Schwartzhoff,
  Vice President - North America Sales and Global Marketing
• Stefanie Cavanaugh,
  Chief Financial Officer, Secretary
• K. Todd Newton,
  Consultant
• Bret Schwartzhoff,
  VP, US Sales & Global Marketing
• Julie Shimer,
  Independent Director
• Bruce Robertson,
  Independent Director
• David Pacitti,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• William McClellan,
  Independent Director
• John Barr,
  Independent Director
• Rick Anderson,
  Independent Director
• John Molesphini,
  Executive Vice President - Operations
• Dr. Christopher J. Gostout M.D.,
  Co-Founder & Chief Medical Officer
• Jeffrey G. Black,
  Chief Financial Officer
• Dr. Pankaj Jay Pasricha FACP, M.D., MBBS,
  Co-Founder
• Dr. Christopher J. Gostout,
  Co-Founder & Chief Medical Officer
• Sydney Chung M.D.,
  Co-Founder and Innovation Partner
• Dr. Peter Benjamin Cotton M.D.,
  Co-Founder and Innovation Partner
• Dr. Robert Hawes M.D.,
  Co-Founder and Innovation Partner
• Anthony Kalloo M.D.,
  Co-Founder and Innovation Partner
• Dr. Sergey Kantsevoy M.D.,
  Co-Founder and Innovation Partner
• Charles S. McKhann,
  CEO, Pres & Director
• Sciences Ii L Pptv Iv, L.P....,
  
• Ventures Llc Remeditex,
  10% owner
• Richard J Meelia,
  Director
• Dennis L. Mc Williams,
  President, CCO
• Ventures Endosurgery, Llc...,
  10% owner
• Holdings A/S Novo,
  10% owner
• John W Creecy,
  Director
• Charles Tribie,
  Executive V.P. of Operations
• Chas Mc Khann,
  President and CEO
• Sciences Ii L Pptv Iv, L.P....,
  
• Sciences Ii L Pptv Iv, L.P....,
  
• Capital, L.P. Stonepine,
  10% owner
• Sciences Ii L Pptv Special ...,
  
• Inc Cpmg,
  
• James W Jr Traweek,
  
• Neil Gagnon,
  10% owner
• Sciences Ii L Pptv Iv, L.P....,
  
• Inc Desai Antal Rohit Cpmg,
  
• Matthew S Crawford,
  10% owner
• Jeffrey G. Black,
  Chief Financial Officer
• Mike Gutteridge,
  VP, Int'l Sales and Marketing
• Sharon O'keefe,
  Director
• Jeannette Bankes,
  Director